Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019

With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. I...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of dermatology 2020-02, Vol.47 (2), p.89-103
Hauptverfasser: Nakamura, Yasuhiro, Asai, Jun, Igaki, Hiroshi, Inozume, Takashi, Namikawa, Kenjiro, Hayashi, Ayato, Fukushima, Satoshi, Fujimura, Taku, Ito, Takamichi, Imafuku, Keisuke, Tanaka, Ryota, Teramoto, Yukiko, Minagawa, Akane, Miyagawa, Takuya, Miyashita, Azusa, Wada, Makoto, Koga, Hiroshi, Sugaya, Makoto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 103
container_issue 2
container_start_page 89
container_title Journal of dermatology
container_volume 47
creator Nakamura, Yasuhiro
Asai, Jun
Igaki, Hiroshi
Inozume, Takashi
Namikawa, Kenjiro
Hayashi, Ayato
Fukushima, Satoshi
Fujimura, Taku
Ito, Takamichi
Imafuku, Keisuke
Tanaka, Ryota
Teramoto, Yukiko
Minagawa, Akane
Miyagawa, Takuya
Miyashita, Azusa
Wada, Makoto
Koga, Hiroshi
Sugaya, Makoto
description With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular‐targeted agents, has drastically changed the nature of treatment for adjuvant and advanced‐stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.
doi_str_mv 10.1111/1346-8138.15151
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2320375878</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2320375878</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5021-dbd5e7eb3959f71d02198c1ff0b3352234e8dd35da6c4edd5f1db2be5eac16283</originalsourceid><addsrcrecordid>eNqFkM9PwjAYhhujEUTP3kwTL14G_UG3zhsRRAkJFz03XfuNjGwU1y2G_97CkIMX20O_vHn65MuL0D0lQxrOiPJxHEnK5ZCKcC9Q_5xcoj7hUkRsTJIeuvF-QwhLBSXXqMdpIhmVcR9lC73TW_CAp1BXunGlWxdGl3jivTOFbgq3xfO2sFAWAXvGq7Y5TtjleH3Oce5qbNomqFzrcQWl3rpKY0Zoeouucl16uDu9A_T5Ovt4eYuWq_n7y2QZGUEYjWxmBSSQ8VSkeUJtyFJpaJ6TjHPBGB-DtJYLq2MzBmtFTm3GMhCgDY2Z5AP01Hl3tftqwTeqKryBsuyWUowzwhMhkwP6-AfduLbehu0CJQjlhMQ8UKOOMrXzvoZc7eqi0vVeUaIO9atD2epQtjrWH348nLxtVoE98799B0B0wHdRwv4_n1pMZ534B8oAjtE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2350130063</pqid></control><display><type>article</type><title>Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Nakamura, Yasuhiro ; Asai, Jun ; Igaki, Hiroshi ; Inozume, Takashi ; Namikawa, Kenjiro ; Hayashi, Ayato ; Fukushima, Satoshi ; Fujimura, Taku ; Ito, Takamichi ; Imafuku, Keisuke ; Tanaka, Ryota ; Teramoto, Yukiko ; Minagawa, Akane ; Miyagawa, Takuya ; Miyashita, Azusa ; Wada, Makoto ; Koga, Hiroshi ; Sugaya, Makoto</creator><creatorcontrib>Nakamura, Yasuhiro ; Asai, Jun ; Igaki, Hiroshi ; Inozume, Takashi ; Namikawa, Kenjiro ; Hayashi, Ayato ; Fukushima, Satoshi ; Fujimura, Taku ; Ito, Takamichi ; Imafuku, Keisuke ; Tanaka, Ryota ; Teramoto, Yukiko ; Minagawa, Akane ; Miyagawa, Takuya ; Miyashita, Azusa ; Wada, Makoto ; Koga, Hiroshi ; Sugaya, Makoto</creatorcontrib><description>With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular‐targeted agents, has drastically changed the nature of treatment for adjuvant and advanced‐stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.</description><identifier>ISSN: 0385-2407</identifier><identifier>EISSN: 1346-8138</identifier><identifier>DOI: 10.1111/1346-8138.15151</identifier><identifier>PMID: 31782186</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Best practice ; Cancer therapies ; Clinical trials ; cutaneous melanoma ; Dermatology - standards ; grade system ; guidelines ; Humans ; immune checkpoint inhibitor ; Immune checkpoint inhibitors ; Japan ; Melanoma ; Melanoma - diagnosis ; Melanoma - therapy ; molecular‐targeted agent ; Patient Care Team - standards ; Radiation Oncology - standards ; Skin cancer ; Skin Neoplasms - diagnosis ; Skin Neoplasms - therapy ; Societies, Medical - standards ; Surgery, Plastic - standards</subject><ispartof>Journal of dermatology, 2020-02, Vol.47 (2), p.89-103</ispartof><rights>2019 Japanese Dermatological Association</rights><rights>2019 Japanese Dermatological Association.</rights><rights>Copyright © 2020 Japanese Dermatological Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5021-dbd5e7eb3959f71d02198c1ff0b3352234e8dd35da6c4edd5f1db2be5eac16283</citedby><cites>FETCH-LOGICAL-c5021-dbd5e7eb3959f71d02198c1ff0b3352234e8dd35da6c4edd5f1db2be5eac16283</cites><orcidid>0000-0001-7817-624X ; 0000-0002-7887-8126 ; 0000-0001-7054-1863 ; 0000-0002-8855-3288 ; 0000-0003-2763-7346 ; 0000-0002-4471-1635 ; 0000-0002-2679-8546 ; 0000-0002-0704-8037 ; 0000-0002-7610-0820 ; 0000-0003-4222-9762 ; 0000-0001-6809-5833 ; 0000-0002-3664-5818 ; 0000-0003-2805-4177 ; 0000-0001-7983-9746 ; 0000-0002-5125-2932 ; 0000-0002-1618-329X ; 0000-0002-0622-7682</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1346-8138.15151$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1346-8138.15151$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31782186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakamura, Yasuhiro</creatorcontrib><creatorcontrib>Asai, Jun</creatorcontrib><creatorcontrib>Igaki, Hiroshi</creatorcontrib><creatorcontrib>Inozume, Takashi</creatorcontrib><creatorcontrib>Namikawa, Kenjiro</creatorcontrib><creatorcontrib>Hayashi, Ayato</creatorcontrib><creatorcontrib>Fukushima, Satoshi</creatorcontrib><creatorcontrib>Fujimura, Taku</creatorcontrib><creatorcontrib>Ito, Takamichi</creatorcontrib><creatorcontrib>Imafuku, Keisuke</creatorcontrib><creatorcontrib>Tanaka, Ryota</creatorcontrib><creatorcontrib>Teramoto, Yukiko</creatorcontrib><creatorcontrib>Minagawa, Akane</creatorcontrib><creatorcontrib>Miyagawa, Takuya</creatorcontrib><creatorcontrib>Miyashita, Azusa</creatorcontrib><creatorcontrib>Wada, Makoto</creatorcontrib><creatorcontrib>Koga, Hiroshi</creatorcontrib><creatorcontrib>Sugaya, Makoto</creatorcontrib><title>Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019</title><title>Journal of dermatology</title><addtitle>J Dermatol</addtitle><description>With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular‐targeted agents, has drastically changed the nature of treatment for adjuvant and advanced‐stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.</description><subject>Best practice</subject><subject>Cancer therapies</subject><subject>Clinical trials</subject><subject>cutaneous melanoma</subject><subject>Dermatology - standards</subject><subject>grade system</subject><subject>guidelines</subject><subject>Humans</subject><subject>immune checkpoint inhibitor</subject><subject>Immune checkpoint inhibitors</subject><subject>Japan</subject><subject>Melanoma</subject><subject>Melanoma - diagnosis</subject><subject>Melanoma - therapy</subject><subject>molecular‐targeted agent</subject><subject>Patient Care Team - standards</subject><subject>Radiation Oncology - standards</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - diagnosis</subject><subject>Skin Neoplasms - therapy</subject><subject>Societies, Medical - standards</subject><subject>Surgery, Plastic - standards</subject><issn>0385-2407</issn><issn>1346-8138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM9PwjAYhhujEUTP3kwTL14G_UG3zhsRRAkJFz03XfuNjGwU1y2G_97CkIMX20O_vHn65MuL0D0lQxrOiPJxHEnK5ZCKcC9Q_5xcoj7hUkRsTJIeuvF-QwhLBSXXqMdpIhmVcR9lC73TW_CAp1BXunGlWxdGl3jivTOFbgq3xfO2sFAWAXvGq7Y5TtjleH3Oce5qbNomqFzrcQWl3rpKY0Zoeouucl16uDu9A_T5Ovt4eYuWq_n7y2QZGUEYjWxmBSSQ8VSkeUJtyFJpaJ6TjHPBGB-DtJYLq2MzBmtFTm3GMhCgDY2Z5AP01Hl3tftqwTeqKryBsuyWUowzwhMhkwP6-AfduLbehu0CJQjlhMQ8UKOOMrXzvoZc7eqi0vVeUaIO9atD2epQtjrWH348nLxtVoE98799B0B0wHdRwv4_n1pMZ534B8oAjtE</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Nakamura, Yasuhiro</creator><creator>Asai, Jun</creator><creator>Igaki, Hiroshi</creator><creator>Inozume, Takashi</creator><creator>Namikawa, Kenjiro</creator><creator>Hayashi, Ayato</creator><creator>Fukushima, Satoshi</creator><creator>Fujimura, Taku</creator><creator>Ito, Takamichi</creator><creator>Imafuku, Keisuke</creator><creator>Tanaka, Ryota</creator><creator>Teramoto, Yukiko</creator><creator>Minagawa, Akane</creator><creator>Miyagawa, Takuya</creator><creator>Miyashita, Azusa</creator><creator>Wada, Makoto</creator><creator>Koga, Hiroshi</creator><creator>Sugaya, Makoto</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7817-624X</orcidid><orcidid>https://orcid.org/0000-0002-7887-8126</orcidid><orcidid>https://orcid.org/0000-0001-7054-1863</orcidid><orcidid>https://orcid.org/0000-0002-8855-3288</orcidid><orcidid>https://orcid.org/0000-0003-2763-7346</orcidid><orcidid>https://orcid.org/0000-0002-4471-1635</orcidid><orcidid>https://orcid.org/0000-0002-2679-8546</orcidid><orcidid>https://orcid.org/0000-0002-0704-8037</orcidid><orcidid>https://orcid.org/0000-0002-7610-0820</orcidid><orcidid>https://orcid.org/0000-0003-4222-9762</orcidid><orcidid>https://orcid.org/0000-0001-6809-5833</orcidid><orcidid>https://orcid.org/0000-0002-3664-5818</orcidid><orcidid>https://orcid.org/0000-0003-2805-4177</orcidid><orcidid>https://orcid.org/0000-0001-7983-9746</orcidid><orcidid>https://orcid.org/0000-0002-5125-2932</orcidid><orcidid>https://orcid.org/0000-0002-1618-329X</orcidid><orcidid>https://orcid.org/0000-0002-0622-7682</orcidid></search><sort><creationdate>202002</creationdate><title>Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019</title><author>Nakamura, Yasuhiro ; Asai, Jun ; Igaki, Hiroshi ; Inozume, Takashi ; Namikawa, Kenjiro ; Hayashi, Ayato ; Fukushima, Satoshi ; Fujimura, Taku ; Ito, Takamichi ; Imafuku, Keisuke ; Tanaka, Ryota ; Teramoto, Yukiko ; Minagawa, Akane ; Miyagawa, Takuya ; Miyashita, Azusa ; Wada, Makoto ; Koga, Hiroshi ; Sugaya, Makoto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5021-dbd5e7eb3959f71d02198c1ff0b3352234e8dd35da6c4edd5f1db2be5eac16283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Best practice</topic><topic>Cancer therapies</topic><topic>Clinical trials</topic><topic>cutaneous melanoma</topic><topic>Dermatology - standards</topic><topic>grade system</topic><topic>guidelines</topic><topic>Humans</topic><topic>immune checkpoint inhibitor</topic><topic>Immune checkpoint inhibitors</topic><topic>Japan</topic><topic>Melanoma</topic><topic>Melanoma - diagnosis</topic><topic>Melanoma - therapy</topic><topic>molecular‐targeted agent</topic><topic>Patient Care Team - standards</topic><topic>Radiation Oncology - standards</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - diagnosis</topic><topic>Skin Neoplasms - therapy</topic><topic>Societies, Medical - standards</topic><topic>Surgery, Plastic - standards</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakamura, Yasuhiro</creatorcontrib><creatorcontrib>Asai, Jun</creatorcontrib><creatorcontrib>Igaki, Hiroshi</creatorcontrib><creatorcontrib>Inozume, Takashi</creatorcontrib><creatorcontrib>Namikawa, Kenjiro</creatorcontrib><creatorcontrib>Hayashi, Ayato</creatorcontrib><creatorcontrib>Fukushima, Satoshi</creatorcontrib><creatorcontrib>Fujimura, Taku</creatorcontrib><creatorcontrib>Ito, Takamichi</creatorcontrib><creatorcontrib>Imafuku, Keisuke</creatorcontrib><creatorcontrib>Tanaka, Ryota</creatorcontrib><creatorcontrib>Teramoto, Yukiko</creatorcontrib><creatorcontrib>Minagawa, Akane</creatorcontrib><creatorcontrib>Miyagawa, Takuya</creatorcontrib><creatorcontrib>Miyashita, Azusa</creatorcontrib><creatorcontrib>Wada, Makoto</creatorcontrib><creatorcontrib>Koga, Hiroshi</creatorcontrib><creatorcontrib>Sugaya, Makoto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakamura, Yasuhiro</au><au>Asai, Jun</au><au>Igaki, Hiroshi</au><au>Inozume, Takashi</au><au>Namikawa, Kenjiro</au><au>Hayashi, Ayato</au><au>Fukushima, Satoshi</au><au>Fujimura, Taku</au><au>Ito, Takamichi</au><au>Imafuku, Keisuke</au><au>Tanaka, Ryota</au><au>Teramoto, Yukiko</au><au>Minagawa, Akane</au><au>Miyagawa, Takuya</au><au>Miyashita, Azusa</au><au>Wada, Makoto</au><au>Koga, Hiroshi</au><au>Sugaya, Makoto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019</atitle><jtitle>Journal of dermatology</jtitle><addtitle>J Dermatol</addtitle><date>2020-02</date><risdate>2020</risdate><volume>47</volume><issue>2</issue><spage>89</spage><epage>103</epage><pages>89-103</pages><issn>0385-2407</issn><eissn>1346-8138</eissn><abstract>With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular‐targeted agents, has drastically changed the nature of treatment for adjuvant and advanced‐stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31782186</pmid><doi>10.1111/1346-8138.15151</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-7817-624X</orcidid><orcidid>https://orcid.org/0000-0002-7887-8126</orcidid><orcidid>https://orcid.org/0000-0001-7054-1863</orcidid><orcidid>https://orcid.org/0000-0002-8855-3288</orcidid><orcidid>https://orcid.org/0000-0003-2763-7346</orcidid><orcidid>https://orcid.org/0000-0002-4471-1635</orcidid><orcidid>https://orcid.org/0000-0002-2679-8546</orcidid><orcidid>https://orcid.org/0000-0002-0704-8037</orcidid><orcidid>https://orcid.org/0000-0002-7610-0820</orcidid><orcidid>https://orcid.org/0000-0003-4222-9762</orcidid><orcidid>https://orcid.org/0000-0001-6809-5833</orcidid><orcidid>https://orcid.org/0000-0002-3664-5818</orcidid><orcidid>https://orcid.org/0000-0003-2805-4177</orcidid><orcidid>https://orcid.org/0000-0001-7983-9746</orcidid><orcidid>https://orcid.org/0000-0002-5125-2932</orcidid><orcidid>https://orcid.org/0000-0002-1618-329X</orcidid><orcidid>https://orcid.org/0000-0002-0622-7682</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0385-2407
ispartof Journal of dermatology, 2020-02, Vol.47 (2), p.89-103
issn 0385-2407
1346-8138
language eng
recordid cdi_proquest_miscellaneous_2320375878
source MEDLINE; Access via Wiley Online Library
subjects Best practice
Cancer therapies
Clinical trials
cutaneous melanoma
Dermatology - standards
grade system
guidelines
Humans
immune checkpoint inhibitor
Immune checkpoint inhibitors
Japan
Melanoma
Melanoma - diagnosis
Melanoma - therapy
molecular‐targeted agent
Patient Care Team - standards
Radiation Oncology - standards
Skin cancer
Skin Neoplasms - diagnosis
Skin Neoplasms - therapy
Societies, Medical - standards
Surgery, Plastic - standards
title Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A45%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Japanese%20Dermatological%20Association%20Guidelines:%20Outlines%20of%20guidelines%20for%20cutaneous%20melanoma%202019&rft.jtitle=Journal%20of%20dermatology&rft.au=Nakamura,%20Yasuhiro&rft.date=2020-02&rft.volume=47&rft.issue=2&rft.spage=89&rft.epage=103&rft.pages=89-103&rft.issn=0385-2407&rft.eissn=1346-8138&rft_id=info:doi/10.1111/1346-8138.15151&rft_dat=%3Cproquest_cross%3E2320375878%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2350130063&rft_id=info:pmid/31782186&rfr_iscdi=true